MADISON, Wis.–(BUSINESS WIRE)–BioForward has announced the winners of the annual Wisconsin Biohealth Awards, dedicated to showcasing leadership and innovation in the Wisconsin biohealth industry. The 2017 winners of the Hector F. DeLuca Scientific Achievement Award and Wisconsin Biohealth Business Achievement Award include Dr. Lynn Allen-Hoffmann and Cynthia LaConte, respectively.

Dr. Lynn Allen-Hoffmann, Founder and former CEO of Stratatech Corporation, now a Mallinckrodt company; current Senior Vice President of Regenerative Medicine at Mallinckrodt; and Professor of Pathology and Laboratory Medicine at University of Wisconsin-Madison, will receive the Hector F. DeLuca Scientific Achievement Award, celebrating her exceptional success in developing regenerative medicine products that have the potential to transform the standard of treatment for burn care and wound healing and founding Stratatech, acquired by Mallinckrodt in 2016.

Cynthia LaConte, CEO and President of The Dohmen Company, will receive the Wisconsin Biohealth Business Achievement Award, honoring her achievements and vision to create a more efficient, effective and easy to use health experience. Under Cynthia’s leadership Dohmen Life Science Services was founded and is now recognized as the leading business process outsourcing company serving the life sciences industry. Cynthia has also fostered Milwaukee’s emerging high-tech healthcare industry through the growth of Dohmen’s Red Arrow Labs.

“These awards are a testament to the dedication and innovation both Dr. Allen-Hoffmann and Cynthia LaConte have put forth in Wisconsin’s biohealth industry,” said Lisa Johnson, CEO of BioForward. “We’re delighted to honor two individuals who have made a significant impact on both global human health and Wisconsin’s economy.”

The Wisconsin Biohealth Awards were launched in 2015, recognizing scientific and business successes that have brought Wisconsin to be among the top leaders in integrated health solutions. Past awardees include Dr. James Thompson of UW-Madison, Ralph Kauten of Lucigen, Dr. Hector DeLuca of UW-Madison and Deltanoid Pharmaceuticals, and Bill Linton of Promega.

Dr. Lynn Allen-Hoffmann and Cynthia LaConte will be honored during a lunch ceremony at the Wisconsin Biohealth Summit presented by BioForward on October 10, 2017, at the Overture Center in Madison, Wisconsin. Additional information on the Wisconsin Biohealth Awards, awardees, and the Wisconsin Biohealth Summit can be found at

About BioForward

BioForward serves as the independent voice of Wisconsin’s biohealth industry, providing services and resources to support the growth of our industry throughout the U.S. and the world. BioForward is the only Wisconsin organization representing over 200 biohealth member companies including biotech, biopharma, medical device, diagnostics, digital health, as well as research institutions, and service providers.

About Dohmen

Founded in 1858, Dohmen has evolved from an apothecary to a portfolio of companies, each serving a unique role in pursuit of Dohmen’s vision of creating an efficient, effective and easy to use health experience. Today, we’re a trusted partner to hundreds of companies – from Fortune 500 to start-up – helping them find efficiencies, obtain more effective health outcomes and improve their customer experience. Learn more about the Dohmen family of companies visit

About Mallinckrodt Pharmaceuticals

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company’s core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit